Exenatide - Intarcia Therapeutics

Drug Profile

Exenatide - Intarcia Therapeutics

Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics; Exenatide subcutaneous implant - Intarcia Therapeutics; Exendin-4; ITCA-650

Latest Information Update: 15 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intarcia Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 03 Mar 2017 Intarcia Therapeutics initiates enrolment in a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA (NCT03060980)
  • 06 Feb 2017 US FDA accepts NDA of ITCA 650 for Type-2 diabetes mellitus for review
  • 21 Nov 2016 Preregistration for Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top